" class="no-js "lang="en-US"> Huyen Tran - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Huyen Tran

Huyen Tran

About Huyen Tran

Professor Huyen Tran is Director of the Ronald Sawers Haemophilia Treatment Centre and the Clinical Thrombosis Service, both of which care for patients with blood disorders. Both groups undertake research in their specialisation, and are associated with the Australian Centre for Blood Diseases and Alfred Health.

Related Story

COVID-19

 ‘We Can Treat It’: Mortality Rate of Rare Condition Linked to AstraZeneca Shot Plunges | Pharmtech Focus

‘We Can Treat It’: Mortality Rate of Rare Condition Linked to AstraZeneca Shot Plunges

June 7 2021

Doctors are now confident they can detect and treat the rare blood clotting syndrome associated […]